BioPharmSignal logoBioPharmSignal

Biotech News

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Alzamend Neuro (ALZN)Alzamend NeuroEarnings

ALZN (ALZN) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is alzn.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

TSHATaysha Gene Therapies2026-11-05 13:00 EST

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

CGTXCognition Therapeutics2026-11-02 12:30 EST

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026

ABOSAcumen Pharmaceuticals2026-10-26 11:00 EST

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

ADXNAddex Therapeutics2026-09-24 05:00 EST

Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026

XENEXenon2026-11-02 21:02 EST

Xenon to Report Q3 2026 Financial Results on November 9, 2026

ABOSAcumen Pharmaceuticals2026-10-19 20:00 EST

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

XERSXeris Pharmaceuticals2026-11-05 12:00 EST

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

HRMYHarmony Biosciences2026-11-04 12:30 EST

Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile

PRAXPraxis Precision Medicines2026-10-27 20:01 EST

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

View all latest news

Alzamend Neuro

Alzamend Neuro is a neuroscience company focused on Alzheimer's disease and other neuropsychiatric disorders. Its story is built around high-risk CNS development and novel treatment approaches.

Recent company news

ALZNAlzamend Neuro2026-09-16 12:00 EST

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

ALZNAlzamend Neuro2026-08-20 12:00 EST

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

ALZNAlzamend Neuro2026-08-18 12:00 EST

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

ALZNAlzamend Neuro2026-08-04 12:00 EST

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

ALZNAlzamend Neuro2026-04-07 12:00 EST

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

Stock data

Close
1.55 USD
Market cap
4.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States